Michael Zile to Clinical Trials as Topic
This is a "connection" page, showing publications Michael Zile has written about Clinical Trials as Topic.
Connection Strength
0.251
-
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
Score: 0.111
-
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 07; 11(7):e004962.
Score: 0.028
-
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30; 135(22):e1054-e1091.
Score: 0.026
-
Natriuretic Peptides, 6-Min Walk Test, and?Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. J Am Coll Cardiol. 2016 Dec 20; 68(24):2690-2707.
Score: 0.025
-
Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014 Apr; 2(2):97-112.
Score: 0.021
-
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014 Jan; 35(1):42-7.
Score: 0.020
-
Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
Score: 0.019